Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
15.5(c) 15.3(c) 15.25(c) 15.15(c) 15.55(c) Last
4 916 388 10 476 5 192 12 499 Volume
+1.64% -1.29% -0.33% -0.66% +2.64% Change
More quotes
Estimated financial data (e)
Sales 2020 0,95 M 1,07 M 1,07 M
Net income 2020 -6,00 M -6,79 M -6,79 M
Net cash position 2020 48,0 M 54,3 M 54,3 M
P/E ratio 2020 -9,09x
Yield 2020 -
Sales 2021 2,65 M 3,00 M 3,00 M
Net income 2021 -13,0 M -14,7 M -14,7 M
Net cash position 2021 42,0 M 47,5 M 47,5 M
P/E ratio 2021 -29,3x
Yield 2021 -
Capitalization 402 M 453 M 454 M
EV / Sales 2020 372x
EV / Sales 2021 136x
Nbr of Employees -
Free-Float 41,0%
More Financials
Company
Hyloris Pharmaceuticals is a Belgium-based specialty pharmaceutical company. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The CompanyÔÇÖs diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms. 
Sector
Pharmaceuticals
Calendar
03/16Earnings Release
More about the company
All news about HYLORIS PHARMACEUTICALS SA
11/15US FDA to Decide on Approval of Hyloris Painkiller Earlier Than Expected
MT
11/15Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic« IV
GL
11/15Hyloris Announces Earlier than Expected PDUFA Date for Maxigesic? IV
CI
11/10Hyloris Starts Strategic Partnership With Pleco Therapeutics
MT
11/10Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
AQ
11/10Hyloris Broadens Pipeline with Novel Patented Combination Product Candidate in Acute My..
CI
11/10Pleco Therapeutics B.V. announced that it expects to receive ?1 million in funding from..
CI
11/02Hyloris Pharmaceuticals Kicks Off Mid-Stage Trial of Vulvovaginal Candidiasis Treatment
MT
11/02Hyloris Announces Start of Phase 2 Study of Miconazole-Domiphen Bromide Vaginal Cream i..
AQ
11/02Hyloris Pharmaceuticals SA Announces Start of Phase 2 Study of Miconazole-Domiphen Brom..
CI
11/01Hyloris Post-Operative Pain Treatment's New Drug Application Gets US FDA Acceptance
MT
11/01Hyloris Announces FDA Acceptance of New Drug Application for Maxigesic« IV in Post-Oper..
GL
11/01Hyloris Pharmaceuticals SA Announces FDA Acceptance of New Drug Application for Maxiges..
CI
10/19HYLORIS PHARMACEUTICALS' : Post-Operative Pain Treatment Gets Regulatory Approvals in UK, ..
MT
10/19HYLORIS PHARMACEUTICALS : Announces Approval of Maxigesic« IV in the UK and Ireland
AQ
More news
News in other languages on HYLORIS PHARMACEUTICALS SA
11/15KBC trekt Brussel in het rood
11/15Brussel verder in het rood
11/15KBC zet Bel20 lager
11/15Bel20 start week lager
11/15La FDA américaine se prononce plus tôt que prévu sur l'autorisation de l'antidouleur Hy..
More news
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | HYL | BE0974363955 | MarketScreener
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 15,55 €
Average target price 17,25 €
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer & Executive Director
Jean-Luc Vandebroek Chief Financial Officer
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA59.47%453
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641